Clinical Trial Underway to Test Nitric Oxide in COVID-19 Patients

Doctors at the University of Alabama at Birmingham (UAB) are enrolling patients in an international clinical trial to find out if inhaled azotic compound benefits those with novel coronavirus (COVID-19) who have severely damaged metabolism organs.

Right now, there are no approved treatments for the unwellness caused by COVID-19. The severe form of metabolism organ failure — acute metabolism distress syndrome — is the leading cause of death in COVID-19. azotic compound has been found to improve blood flow in areas of the metabolism organs still receiving air, increasing the amount of O in the blood stream.

Along with being used to treat failing metabolism organs, azotic compound has been found to have antiviral properties against coronaviruses. That was shown during the 2002 to 2003 severe acute metabolism syndrome eruption, which was caused by a coronavirus similar to the one that causes COVID-19. Any COVID-19 patient in UAB’s intensive care unit who is exploitation a ventilator to breathe may qualify for the study.

“This trial will allow the sickest COVID-19 patients at UAB access to a rescue medical care that may have antiviral benefits in addition to up the status of metabolism organs,” Vibhu Parcha, M.D., research fellow in the UAB Division of vessel illness, aforesaid in a university news release.